Jet nebulization of prostaglandin E1 during neonatal mechanical ventilation: Stability, emitted dose and aerosol particle size

Pharmacological Research

Volumn 56, Issue 6, 2007, Pages 531-541

  Sood, Beena G ^a   Peterson, Jennifer ^d   Malian, Monica ^c   Galli, Robert ^c   Geisor Walter, Maria ^c   McKinnon, Jon ^d   Sharp, Jody ^a   Maddipati, Krishna Rao ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^d WestMed Inc   (United States)

Author keywords

Aerosol; Aerosol particle size distribution; Cascade impactor; Chemical stability; Emitted dose; Jet nebulizer; LC MS; Mechanical ventilation; Nebulizer; Neonatal hypoxemic respiratory failure; Prostaglandin E1 PGE1 Alprostadil; Pulmonary deposition; Respirable fraction

Indexed keywords

PROSTAGLANDIN E1;

AEROSOL; ARTICLE; ARTIFICIAL VENTILATION; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG SOLUTION; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; JET VENTILATION; MASS SPECTROMETRY; NEBULIZATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SURFACE TENSION;

AEROSOLS; ALPROSTADIL; DRUG STABILITY; HUMANS; INFANT, NEWBORN; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; RESPIRATION, ARTIFICIAL; VASODILATOR AGENTS;

EID: 36248973717     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.09.017     Document Type: Article

References (43)

1. NINOS (The Neonatal Inhaled Nitric Oxide Study Group). Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 336 (1997) 597-604
2. Walmrath D., Schermuly R., Pilch J., Grimminger F., and Seeger W. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J 10 (1997) 1084-1092
3. Meyer J., Theilmeier G., Van Aken H., Bone H.G., Busse H., Waurick R., et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg 86 (1998) 753-758
4. Putensen C., Hormann C., Kleinsasser A., and Putensen-Himmer G. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 157 (1998) 1743-1747
5. 1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a phase i/ii open label clinical trial. Pediatr Res 56 (2004) 579-585
6. Youngerand E.W., and Szabo R.M. The stability of prostaglandin E1 in dilute physiological solutions at 37 °C. Prostaglandins 31 (1986) 923-927
7. Krakoff L.R., Vlachakis N., Mendlowitz M., and Stricker J. Differential effect of prostaglandin A1 in hypertensive patients with low, normal, and high renin. Clin Sci Mol Med 2 (1975) 311s-313s
8. Peskar B.A., Cawello W., Rogatti W., and Rudofsky G. On the metabolism of prostaglandin E1 administered intravenously to human volunteers. J Physiol Pharmacol 42 (1991) 327-331
9. Thiel C.G. Cascade impactor data and the lognormal distribution: non-linear regression for a better fit. J Aerosol Med 15 (2002) 369-378
10. USP. General Chapter (601) Aerosols, vol. 1912 (2000), United States Pharmacopeial Convention, Inc., Rockville, MD
11. 1 in humans and swine. Transplantation 61 (1996) 1624-1629
12. Drummond W.H., Gregory G.A., Heymann M.A., and Phibbs R.A. The independent effects of hyperventilation, tolazoline, and dopamine on infants with persistent pulmonary hypertension. J Pediatr 98 (1981) 603-611
13. Graves III E.D., Redmond C.R., and Arensman R.M. Persistent pulmonary hypertension in the neonate. Chest 93 (1988) 638-641
14. 1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology 70 (1989) 601-606
15. Walsh-Sukys M.C., Tyson J.E., Wright L.L., Bauer C.R., Korones S.B., Stevenson D.K., et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 105 (2000) 14-20
16. Sangwan S., Condos R., and Smaldone G.C. Lung deposition and respirable mass during wet nebulization. J Aerosol Med 16 (2003) 379-386
17. Siobal M.S., Kallet R.H., Pittet J.F., Warnecke E.L., Kraemer R.W., Venkayya R.V., et al. Description and evaluation of a delivery system for aerosolized prostacyclin. Respir Care 48 (2003) 742-753
18. Hess D., Fisher D., Williams P., Pooler S., and Kacmarek R.M. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 110 (1996) 498-505
19. Pharmacopoeia U.S. (2000), United States Pharmacopeial Convention, Inc., Rockville p. 65-67
20. Dennis J.H. Standardization issues: in vitro assessment of nebulizer performance. Respir Care 47 (2002) 1445-1455 discussion 1445-1448
21. Coleman D.M., Kelly H.W., and McWilliams B.C. Determinants of aerosolized albuterol delivery to mechanically ventilated infants. Chest 109 (1996) 1607-1613
22. Tandon R., McPeck M., and Smaldone G.C. Measuring nebulizer output. Aerosol production vs. gravimetric analysis. Chest 111 (1997) 1361-1365
23. Ip A.Y., Arakawa T., Silvers H., Ransone C.M., and Niven R.W. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization. J Pharm Sci 84 (1995) 1210-1214
24. Newman S.P., Pitcairn G.R., Hooper G., and Knoch M. Efficient drug delivery to the lungs from a continuously operated open-vent nebulizer and low-pressure compressor system. Eur Respir J 7 (1994) 1177-1181
25. Awbery J.H., and Inst F.P. The water content of saturated air at temperatures up to 100 °C. Proc Phy Soc 44 (1932) 143-150
26. CRC Handbook of chemistry and physics (1985), CRC Press, Inc., Boca Raton
27. Dhand R. Aerosol therapy during mechanical ventilation: getting ready for prime time. Am J Respir Crit Care Med 168 (2003) 1148-1149
28. Fink J.B., Dhand R., Grychowski J., Fahey P.J., and Tobin M.J. Reconciling in vitro and in vivo measurements of aerosol delivery from a metered-dose inhaler during mechanical ventilation and defining efficiency-enhancing factors. Am J Respir Crit Care Med 159 (1999) 63-68
29. Di Paolo E.R., Pannatier A., and Cotting J. In vitro evaluation of bronchodilator drug delivery by jet nebulization during pediatric mechanical ventilation. Pediatr Crit Care Med 6 (2005) 462-469
30. Dijk P.H., Heikamp A., Piers D.A., Weller E., Bambang S., and Oetomo. Surfactant nebulisation: safety, efficiency and influence on surface lowering properties and biochemical composition. Intensive Care Med 23 (1997) 456-462
31. McPeck M., Tandon R., Hughes K., and Smaldone G.C. Aerosol delivery during continuous nebulization. Chest 111 (1997) 1200-1205
32. Pelkonen A.S., Nikander K., and Turpeinen M. Jet nebulization of budesonide suspension into a neonatal ventilator circuit: synchronized versus continuous nebulizer flow. Pediatr Pulmonol 24 (1997) 282-286
33. Briant J.K., Frank D.D., James A.C., and Eyler L.L. Numerical simulation of aerosol particle transport by oscillating flow in respiratory airways. Ann Biomed Eng 20 (1992) 573-581
34. Schererand P.W., and Haselton F.R. Convective exchange in oscillatory flow through bronchial-tree models. J Appl Physiol: Resp Environ Exer Physiol 53 (1982) 1023-1033
35. Coates A.L., Allen P.D., MacNeish C.F., Ho S.L., and Lands L.C. Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis. Chest 119 (2001) 1123-1130
36. Dijk P.H., Heikamp A., and Oetomo S.B. Surfactant nebulization versus instillation during high frequency ventilation in surfactant-deficient rabbits. Pediatr Res 44 (1998) 699-704
37. McCallion O.N., Taylor K.M., Thomas M., and Taylor A.J. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm Res 12 (1995) 1682-1688
38. Katz S.L., Adatia I., Louca E., Leung K., Humpl T., Reyes J.T., et al. Nebulized therapies for childhood pulmonary hypertension: an in vitro model. Pediatr Pulmonol 41 (2006) 666-673
39. Barryand P.W., and O'Callaghan C. An in vitro analysis of the output of salbutamol from different nebulizers. Eur Respir J 13 (1999) 1164-1169
40. Schuepp K.G., Jauernig J., Janssens H.M., Tiddens H.A., Straub D.A., Stangl R., et al. In vitro determination of the optimal particle size for nebulized aerosol delivery to infants. J Aerosol Med 18 (2005) 225-235
41. Clay M.M., Pavia D., Newman S.P., and Clarke S.W. Factors influencing the size distribution of aerosols from jet nebulizers. Thorax 38 (1983) 755-759
42. Berlinskiand A., and Waldrep J.C. Four hours of continuous albuterol nebulization. Chest 114 (1998) 847-853
43. Stapleton K.W., and Finlay W.H. Errors in characterizing nebulized particle size distributions with cascade impactors. J Aerosol Med 11 Suppl. 1 (1998) S80-S83